EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease

Danna Jennings iD, Sarah Huntwork-Rodriguez, Maurits F J M Vissers iD, Vinay M Daryani iD, Dolores Diaz, Marisa S Goo iD, John J Chen, Romeo Maciuca iD, Kyle Fraser iD, Omar S Mabrouk iD, Jeroen van de Wetering de Rooij, Jules A A C Heuberger iD und 10 weitere

Movement Disorders · 2023-03 · 38 (3) · 386-398

DOI: 10.1002/mds.29297 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Movement Disorders, online erschienen am 18.02.2023. Verfasst von Danna Jennings und 21 weiteren Autor:innen. Beteiligte Einrichtung: SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Parkinson Disease. Die Arbeit wurde bisher 141-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Denali Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Leucine‐rich repeat kinase 2 ( LRRK2 ) inhibition is a promising therapeutic approach for the treatment of Parkinson's disease (PD).

Objective

The aim of this study was to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the potent, selective, CNS‐penetrant LRRK2 inhibitor BIIB122 (DNL151) in healthy participants and patients with PD.

Methods

Two randomized, double‐blind, placebo‐controlled studies were completed. The phase 1 study (DNLI‐C‐0001) evaluated single and multiple doses of BIIB122 for up to 28 days in healthy participants. The phase 1b study (DNLI‐C‐0003) evaluated BIIB122 for 28 days in patients with mild to moderate PD. The primary objectives were to investigate the safety, tolerability, and plasma pharmacokinetics of BIIB122. Pharmacodynamic outcomes included peripheral and central target inhibition and lysosomal pathway engagement biomarkers.

Results

A total of 186/184 healthy participants (146/145 BIIB122, 40/39 placebo) and 36/36 patients (26/26 BIIB122, 10/10 placebo) were randomized/treated in the phase 1 and phase 1b studies, respectively. In both studies, BIIB122 was generally well tolerated; no serious adverse events were reported, and the majority of treatment‐emergent adverse events were mild. BIIB122 cerebrospinal fluid/unbound plasma concentration ratio was ~1 (range, 0.7–1.8). Dose‐dependent median reductions from baseline were observed in whole‐blood phosphorylated serine 935 LRRK2 (≤98%), peripheral blood mononuclear cell phosphorylated threonine 73 pRab10 (≤93%), cerebrospinal fluid total LRRK2 (≤50%), and urine bis (monoacylglycerol) phosphate (≤74%).

Conclusions

At generally safe and well‐tolerated doses, BIIB122 achieved substantial peripheral LRRK2 kinase inhibition and modulation of lysosomal pathways downstream of LRRK2, with evidence of CNS distribution and target inhibition. These studies support continued investigation of LRRK2 inhibition with BIIB122 for the treatment of PD. © 2023 Denali Therapeutics Inc and The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseHumansLeukocytes, MononuclearHealthy VolunteersLeucine-Rich Repeat Serine-Threonine Protein Kinase-2BiomarkersMutation

Stichwörter der Autor:innen

LRRK2 inhibitorParkinson's diseaseclinical trials

Substanzen

Leucine-Rich Repeat Serine-Threonine Protein Kinase-2BiomarkersLRRK2 protein, human

Autor:innen und Institutionen

  • SeniorClinical Scientist - Clinical Development, Denali Therapeutics Inc, South San Francisco, California, USA.
  • Centre for Human Drug Research, Leiden, the Netherlands.
  • Department of Clinical Neuropharmacology, Leiden University Medical Center, Leiden, the Netherlands.
  • Biogen Inc, Cambridge, Massachusetts, USA.
  • PRA Health Sciences, Groningen, the Netherlands.

ORCID-Profile: Danna Jennings, Maurits F J M Vissers, Vinay M Daryani, Marisa S Goo, Romeo Maciuca, Kyle Fraser, Omar S Mabrouk, Jules A A C Heuberger, Geert Jan Groeneveld, Marie T Borin, Andrés Cruz-Herranz, Kimberly Scearce-Levie, Javier De Vicente, Anastasia G Henry, Carole Ho, Matthew D Troyer

Förderung

  • Denali Therapeutics

Zitieren

APA

Jennings, D., Huntwork-Rodriguez, S., Vissers, M. F. J. M., Daryani, V. M., Diaz, D., Goo, M. S., Chen, J. J., Maciuca, R., Fraser, K., Mabrouk, O. S., van de Wetering de Rooij, J., Heuberger, J. A. A. C., Groeneveld, G. J., Borin, M. T., Cruz-Herranz, A., Graham, D., Scearce-Levie, K., De Vicente, J., Henry, A. G., …, & Troyer, M. D. (2023). LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Movement Disorders, 38(3), 386-398. https://doi.org/10.1002/mds.29297

Vancouver

Jennings D, Huntwork-Rodriguez S, Vissers MFJM, Daryani VM, Diaz D, Goo MS, et al. LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease. Movement Disorders. 2023;38(3):386-398. doi:10.1002/mds.29297

BibTeX
@article{Jennings2023,
  author = {Jennings, Danna and Huntwork-Rodriguez, Sarah and Vissers, Maurits F J M and Daryani, Vinay M and Diaz, Dolores and Goo, Marisa S and Chen, John J and Maciuca, Romeo and Fraser, Kyle and Mabrouk, Omar S and van de Wetering de Rooij, Jeroen and Heuberger, Jules A A C and Groeneveld, Geert Jan and Borin, Marie T and Cruz-Herranz, Andrés and Graham, Danielle and Scearce-Levie, Kimberly and De Vicente, Javier and Henry, Anastasia G and Chin, Peter and Ho, Carole and Troyer, Matthew D},
  title = {LRRK2 Inhibition by BIIB122 in Healthy Participants and Patients with Parkinson's Disease},
  journal = {Movement Disorders},
  year = {2023},
  volume = {38},
  number = {3},
  pages = {386--398},
  doi = {10.1002/mds.29297}
}
Kostenlos starten →